AUTHORS
Charalampia Kyriakou, MD, PhD, Mathilde Fekom, PhD2, Nour Moukalled3, Jose Antonio Perez-Simon, MD, PhD4, Peter Pal Remenyi5, Stephanie Nguyen Quoc6, Raynier Devillier, PhD7, Edouard Forcade, MD, PhD8, Romain Gounot9, Maija Itälä-Remes10, Linde Morsink11, Jurgen Kuball, MD12, Olivier Tournilhac, MD, PhD13, Ali Bazarbachi14
AFFILIATIONS
1 University College London Hospitals NHS Foundation Trust, London, United Kingdom
2 European Bone Marrow Transplantation Lymphoma Working Party, Paris, France
3 American University of Beirut Medical Center, Haematology, Beirut, Lebanon
4 Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), CSIC, Sevilla, Spain
5 Del-pesti Centrumkorhaz, Budapest, Hungary
6 Universite Paris IV, Hopital la Pitie-Salpetriere, Paris, France
7 Institut Paoli-Calmettes (IPC), Programme de Transplantation&Therapie Cellulaire, Marseille, Marseille, France
8 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
9 Hôpital Henri-Mondor (AP-HP, Créteil), Creteil, France
10 Turku University Hospital (TYKS), Turku, Finland
11 University Medical Center Groningen (UMCG), Rijks University Groningen (RUG), Groningen, Netherlands
12 University Medical Centre Utrecht, Ultrecht, Netherlands
13 CHU Estaing, Université Clermont-Ferrand, Clermont-Ferrand, France
14 American University of Beirut Medical Center, Beirut, Lebanon
ABSTRACT
Introduction
Waldenström macroglobulinaemia (WM) is a rare, indolent B-cell lymphoma with substantial outcome improvements following the use of Bruton tyrosine kinase (BTK), proteosome (PI) and BCL-2 inhibitors. However, WM remains incurable, and progressive disease (PD) and resistance to treatment continue to require effective salvage strategies. The role of autologous (ASCT) and allogeneic haematopoietic stem cell transplantation (alloSCT) as potential treatments in the era of targeted agents are not well defined.
Methods:
This is an EBMT LWP registry analysis evaluating the SCT outcomes in patients with WM having undergone an ASCT or alloSCT over the last decade (2015-2024).
Results:
Two hundred and sixty-one patients with WM underwent an ASCT between 2015-2024 (n=151 between 2015-2019, n=110 between 2019-2024). The median age at ASCT was 59 (53-64) years and 184 (70%) patients were male. The Karnofsky performance status (KFS) was ≥90 in 180 (76%) of the patients. 144 (55%) patients were transplanted in >24 months from diagnosis. The disease status at ASCT was very good partial response (VGPR) in 63 (25%), partial response (PR) in 160 (65%), stable/progressive disease SD/PD) in 24 (10%) and was missing in 14 patients. The conditioning regimen was BEAM based in 121 (47%), melphalan in 52 (20%) and other in 88 (34%). 66 (25%) received proteosome inhibitor-based treatment prior to ASCT, 32 (12%) BTKi and 1 had prior BCL2 inhibitor treatment (90 (34%) were exposed in both PI and BTKi as part of prior to ASCT therapy lines). The median follow up was 4.3 (2.7-5.6) years. The overall survival rates (OS) at 3 and 5 years were 84.1 and 71.8% respectively, the progression free survival (PFS) 60.5% and 49.5%, the relapse incidence (RI) 34.6% and 44.3% and non-relapse mortality (NRM) 4.9% and 6.2% respectively. The patients transplanted in >24 months from diagnosis had significantly inferior PFS 54.7% vs 69.6% (p= 0.028), with trend for higher RI 38.2% vs 29.1% at 3 years. For patients who had previously BTKi there was trend for shorter post ASCT PFS 43.9% vs 62.8% (p=0.062) at 3 years and higher RI 51.6% vs 32.2% (0.061). SD/PD disease status at transplant were associated with significantly inferior OS 68.9% vs 92.4% (p=0.007) at 2 years and higher NRM 13.2% vs 2.7% (p=0.015). 41 patients died, 22 of PD, 3 of secondary malignancy and 6 of treatment related mortality.
Ninety patients underwent an alloSCT between 2015-2024, 59 (66%) were male, had a median age at alloSCT of 56 (45-64) years and KPS ≥90% in 55 (68%). Twenty-five (28%) patients were transplanted in ≤24 months from diagnosis. 23 (26%) received a PI prior to alloSCT, 33 (37%) a BTKi, 10 (11%) a BCL2 inhibitor and 43 (48%) received more than 1 inhibitor as part of prior to alloSCT therapy lines. 24 (27%) had received an ACT prior to alloSCT. The disease status at alloSCT was VGPR for 32 (37%), PR for 44 (51%) and SD/PD for 11 (13%). The conditioning was myeloablative in 26 (30%) and 61(70%) reduced intensity. The donor type was related in 44 and unrelated in 39. The median follow up was 3.1 (2.3-4.3) years. The OS rates at 3 and 5 years were 59.1% and 59.1%, the PFS 54.6% and 48.5%, RI 23.3% and 29.4% and NRM at 1, 3 and 5 years of 16.3%, 22.1% and 22.1% respectively. The prior use of ASCT and the disease status at alloSCT, did not significantly impact on the OS, PFS, RI or NRM outcomes. BTKi use in prior to alloSCT therapy lines, was significantly associated with lower RI (p= 0.026) and patients receiving alloSCT >24 months had significantly superior OS (p=0.035). The incidence of grade III-IV acute GVHD was 11%. The chronic GVHD was 34% and 45% at 1 and 5 years (extended cGVHD was 2% and 4%). Thirty-two patients died, 10 from progressive disease and 14 from treatment related causes.
Conclusion:
In this large EBMT registry retrospective analysis, both ASCT and alloSCT remain feasible salvage treatments for selected patients with relapsed WM in the era of targeted therapies. ASCT was associated with encouraging long-term disease control (PFS 61%/50% at 3 and 5 years) and low NRM, although outcomes appeared less favourable in patients previously exposed to BTK inhibitors, those transplanted later in the disease course, and those with active disease at ASCT. AlloSCT provided durable disease control (PFS 55%/49% at 3 and 5 years) with a lower RI but was associated with substantial NRM, highlighting the balance between curative potential and transplant-related toxicity.
DISCLOSURES
Charalampia Kyriakou, MD, PhD: No relevant conflicts of interest to declare.